Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Analytik Jena to Develop Products for Sepsis Diagnostics

Published: Tuesday, May 07, 2013
Last Updated: Tuesday, May 07, 2013
Bookmark and Share
Cooperation to continue with the scientific centers for sepsis research in Jena.

Analytik Jena has acquired all of the assets of the insolvent company SIRS-Lab GmbH as part of an asset deal. A contract covering the deal was signed by the Jena-based instrument manufacturer and the insolvency administrator LEONHARDT.

SIRS-Lab, a company that develops molecular diagnostics methods and testing systems for life-threatening infections like sepsis, had filed for insolvency in December 2012.

Analytik Jena AG, which as part of the acquisition will also take on the entire range of product expertise, including more than 50 patents and 10 employees at the Jena site, will for the first time be entering the worldwide growth market of sepsis diagnostics, continuing the intensive development work and the expertise of SIRS-Lab in this field.

"In recent years, SIRS-Lab has built up considerable competence in the field of sepsis analytics and has achieved initial successes. The results from a first application study are highly promising. The aim is to identify life-threatening infections quickly and early. In particular, the region around Jena with the University Hospital and various research institutions offers excellent conditions to allow us to be able to serve this large market with products in the future," says Klaus Berka, CEO of Analytik Jena AG.

SIRS-Lab was founded in 2000 as a spin-off of the Friedrich Schiller University at the Jena Sepsis Competence Center by a high-caliber team of scientists of international renown with the aim of combating the high mortality rate associated with sepsis (blood poisoning).

Among the founders were such renowned scientists as Prof. Dr. Konrad Reinhart, Director of the Clinic for Anesthesiology and Intensive Medicine, Prof. Dr. Eberhard Straube, former Director of the Institute for Medical Microbiology at the University of Jena, and Prof. Dr. Hanspeter Saluz, Head of the Cell and Molecular Biology department at the Hans-Knöll Institute in Jena.

With the product LOOXSTER®, the company developed a patented technology for concentrating bacterial and fungal DNA in diagnostic samples. This product has been used in VYOO®, the CE-certified product for sepsis diagnostics.

SIRS-Lab was also developing an innovative gene expression product (SIQNATURE®) to indicate the body's immune response to an infection.

A related test developed by SIRS-Lab is almost ready for the market. All SIRS-Lab developments are designed to enable improved and faster diagnostics on patients with systemic infections.

"I am delighted that, in the form of Analytik Jena, an investor has been found who will continue the valuable work that has been carried out in recent years in the field of the diagnosis of life-threatening infections, continuing the fight against sepsis," says Prof. Konrad Reinhart, Director of the Clinic for Anesthesiology and Intensive Therapy (KAI) at the University Hospital of Jena.

Analytik Jena, which is already profiting from revenue in the public healthcare sector in the field of life science, has set out plans to focus more strongly on routine diagnostics and to work more closely with hospital and clinical partners in the process.

SIRS-Lab was a member of the German Sepsis Society and collaborated with many internationally renowned partners, including the University Hospital of the Friedrich Schiller University Jena, which only received the green light from an international jury of experts to develop an integrated research and treatment center for sepsis and related illnesses in January 2010.

"We also see our commitment in a regional context," explains Berka. Accordingly, one of the main concerns is to keep important expertise and research and development capacities at the site.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Analytik Jena Opens Swiss Branch Office in Reinach
Direct service and supply for Analytical Instrumentation customers in the Swiss market.
Thursday, October 29, 2015
Analytik Jena AG Supports Bone Marrow Donation Organization
Company to support DKMS in the fight against blood cancer.
Saturday, June 20, 2015
Analytik Jena AG Receives Major Order from China
Delivery of EUR 2.5 m in instruments from both core business units of Analytical Instrumentation and Life Science.
Friday, May 08, 2015
Analytik Jena to Acquire Bruker’s ICP-MS Business
Analytik Jena AG has signed a binding agreement to acquire the ICP-MS business of Bruker, the transaction is expected to close in September 2014.
Monday, August 18, 2014
Analytik Jena AG Completes Merger of CyBio AG
Merger became effective upon entry into the commercial register of Analytik Jena AG.
Thursday, July 10, 2014
Analytik Jena CEO Klaus Berka Becomes an Advisor of the Fraunhofer IZI
Klaus Berka to advise the institute's management and the Executive Board of the Fraunhofer Gesellschaft.
Saturday, May 17, 2014
CyBio to be Merged into Analytik Jena
Analytik Jena AG is planning to merge the business of its subsidiary CyBio AG with its core business in the Life Science business unit.
Friday, April 11, 2014
Analytik Jena Appoints New MD at Japanese Subsidiary
Dr. Marco Tilgner has been appointed new managing director of the Japanese subsidiary AJ Japan as of January 1, 2014.
Monday, December 09, 2013
Analytik Jena Subsidiary Obtained Approval for Two New Assays
ELISA-based tests for detection of PRRSV.
Monday, July 01, 2013
Analytik Jena Establishes Subsidiary in Thailand
New company to bolster Analytik Jena’s activities in the Southeast Asian market.
Tuesday, May 07, 2013
Analytik Jena to Develop Products for Sepsis Diagnostics
Integration of a core team of former employees in the Life Science business unit. Cooperation to continue with the scientific centers for sepsis research in Jena.
Tuesday, May 07, 2013
Analytik Jena Increases Stake in Ilmenau-Based ETG to 80.0%
ETG already generates approximately 85.0% of its sales with Analytik Jena.
Friday, April 12, 2013
Analytik Jena AG Acquires UVP, LLC
UVP is a globally-operating provider of predominantly digital imaging systems for applications in proteomics, genomics and plant and animal sciences.
Tuesday, April 02, 2013
Analytik Jena Increases Stake in its Subsidiary AJ Roboscreen to 100%
The Jena-based manufacturer of analytical instrumentation technology, life science instruments and optoelectronics has thus integrated another subsidiary further into the Group.
Monday, April 23, 2012
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
Grant Supports Project To Develop Simple Test To Screen For Cervical Cancer
UCLA Engineering announces funding from Bill and Melinda Gates Foundation.
Injecting New Life into Old Antibiotics
A new fully synthetic way to make a class of antibiotics called macrolides from simple building blocks is set to open up a new front in the fight against antimicrobial drug resistance.
Insight into Bacterial Resilience and Antibiotic Targets
Variant of CRISPR technology paired with computerized imaging reveals essential gene networks in bacteria.
Advancing Protein Visualization
Cryo-EM methods can determine structures of small proteins bound to potential drug candidates.
Alzheimer’s Protein Serves as Natural Antibiotic
Alzheimer's-associated amyloid plaques may be part of natural process to trap microbes, findings suggest new therapeutic strategies.
Slime Mold Reveals Clues to Immune Cells’ Directional Abilities
Study from UC San Diego identifies a protein involved in the directional ability of a slime mold.
How Do You Kill A Malaria Parasite?
Drexel University scientists have discovered an unusual mechanism for how two new antimalarial drugs operate: They give the parasite’s skin a boost in cholesterol, making it unable to traverse the narrow labyrinths of the human bloodstream. The drugs also seem to trick the parasite into reproducing prematurely.
Illuminating Hidden Gene Regulators
New super-resolution technique visualizes important role of short-lived enzyme clusters.
Supressing Intenstinal Analphylaxis in Peanut Allergy
Study from National Jewish Health shows that blockade of histamine receptors suppresses intestinal anaphylaxis in peanut allergy.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!